DURACLON
Clinical safety rating: caution
Comprehensive clinical and safety monograph for DURACLON (DURACLON).
Alpha-2 adrenergic receptor agonist in the pontine locus coeruleus, reducing central sympathetic outflow and norepinephrine release, thereby decreasing blood pressure, heart rate, and opioid withdrawal symptoms.
| Metabolism | Primarily hepatic via CYP2D6 (50%), also CYP1A2 and CYP3A4. Undergoes extensive first-pass metabolism; about 50% of dose metabolized in the liver. |
| Excretion | Clonidine (DURACLON) is primarily excreted renally. Approximately 40-60% is excreted unchanged in urine, with the remainder as metabolites (mainly p-hydroxyclonidine). Fecal excretion accounts for ~20% of elimination; biliary excretion is minimal (<5%). |
| Half-life | Terminal elimination half-life is 12-16 hours in patients with normal renal function. In renal impairment, it may extend to 30-40 hours, necessitating dose adjustment. The half-life supports twice-daily dosing for epidural formulations. |
| Protein binding | 20-40% bound to plasma proteins (albumin and alpha-1-acid glycoprotein). Binding is not saturable at therapeutic concentrations. |
| Volume of Distribution | 2.1-3.5 L/kg. High Vd indicates extensive tissue distribution, including brain (crosses blood-brain barrier) and placenta. |
| Bioavailability | Oral: 75-95% (mean ~80%); Epidural: Near 100% (direct vascular absorption); Transdermal: 75-90% (relative to oral, but system-dependent). |
| Onset of Action | Oral: 30-60 minutes; Epidural: 30 minutes; Transdermal: 2-3 days (continuous delivery). Peak effect for oral occurs at 2-4 hours; for epidural, at 30-60 minutes. |
| Duration of Action | Oral: 6-12 hours; Epidural: 4-8 hours (dose-dependent); Transdermal: 7 days (system provides steady-state after 2-3 days). |
Epidural or intrathecal: 30 mcg/hour continuous epidural infusion (300 mcg/mL concentration) or 100-600 mcg/day intrathecal infusion as part of multimodal analgesia; not for bolus administration. Intravenous: 0.3-2.4 mcg/kg/hour continuous infusion for ICU sedation (off-label use).
| Dosage form | INJECTABLE |
| Renal impairment | No specific dose adjustment recommended; clonidine is minimally renally excreted, but accumulation of metabolites may occur in severe renal impairment (GFR <30 mL/min). Use with caution and monitor for excessive hypotension and bradycardia. |
| Liver impairment | Child-Pugh Class A/B: No dosage adjustment required. Child-Pugh Class C: Reduce starting dose by 50% and titrate cautiously due to decreased clearance. |
| Pediatric use | Neonates/infants: 0.5-1 mcg/kg intravenous loading followed by 0.5-2 mcg/kg/hour continuous infusion for sedation (off-label). Children >1 month: 0.5-4 mcg/kg intravenous loading then 0.5-10 mcg/kg/hour infusion; epidural: 0.2-2 mcg/kg/hour. Maximum rate: 10 mcg/kg/hour. |
| Geriatric use | Elderly patients (>65 years): Start at lowest effective dose (e.g., 0.1-0.2 mcg/kg/hour intravenous infusion). Increase dose gradually due to increased sensitivity to hypotensive and sedative effects. Epidural: reduce infusion rate by 25-50%. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for DURACLON (DURACLON).
| Breastfeeding | Clonidine is excreted in human breast milk with a milk-to-plasma ratio of approximately 0.72. Peak milk concentrations occur 2–4 hours after dose. Monitor infant for hypotension, bradycardia, and irritability. Caution is advised. |
| Teratogenic Risk | Clonidine (DURACLON) is classified as FDA Pregnancy Category C. Animal studies have shown increased fetal resorptions and developmental delays at high doses. No adequate human studies exist. First trimester: potential risk of teratogenicity unknown; second and third trimesters: associated with reduced fetal heart rate variability and temperature regulation. Use only if benefit outweighs risk. |
■ FDA Black Box Warning
Epidural administration is contraindicated in patients with bleeding disorders or anticoagulant therapy due to risk of epidural hematoma.
| Serious Effects |
Hypersensitivity to clonidine; epidural use in patients with bleeding diathesis or receiving anticoagulant therapy; severe bradycardia or sick sinus syndrome (absolute); caution in pregnancy (Category C) and breastfeeding.
| Precautions | Rebound hypertension after abrupt discontinuation; risk of bradycardia, hypotension, and syncope; use with caution in patients with cardiovascular disease, renal impairment, or Parkinson's disease; may cause sedation and dry mouth. |
Loading safety data…
| Fetal Monitoring | Monitor maternal blood pressure and heart rate regularly. Fetal heart rate monitoring is recommended due to potential for decreased fetal heart rate variability. Assess for maternal sedation and signs of withdrawal if therapy is discontinued. |
| Fertility Effects | Clonidine may cause reversible changes in libido and sexual function in males. No specific data on female fertility; animal studies show no significant fertility impairment. |